protect your lecture notes field please! Checked dynamed - agreed on glucocorticoids (though much of a muchness), sort of agree on tocilizumab: ’ use immunosuppressants as adjunctive therapy in patients with refractory or relapsing disease, and in patients with or at increased risk of glucocorticoid related adverse effects or complications’
for patients in the above group, tocilizumab is first line (in conjunction with glucocorticoids)
edits made - will leave up to someone else whether this is a change worth making
amboss agrees so approving